In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.

Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses / Ferolla, P; Faggiano, A; Grimaldi, F; Ferone, D; Scarpelli, G; Ramundo, V; Severino, R; Bellucci, M C; Camera, L M; Lombardi, G; Angeletti, G; Colao, A. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 35:3(2012), pp. 326-331. [10.3275/7869]

Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses

Faggiano, A;Ramundo, V;
2012

Abstract

In patients with well-differentiated (WD) neuroendocrine tumors (NET), long-acting octreotide (LAR), conventionally administered at a dose of 30 mg every 28 days, has well-documented anti-secretive but limited antiproliferative effects.
File allegati a questo prodotto
File Dimensione Formato  
Ferolla_Long-acting-octreotide_2012.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 155.64 kB
Formato Adobe PDF
155.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1120816
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 48
social impact